Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Szabo

Showing results (1-10 of 220) with videos related to

Pageof 22
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|January 28, 2010
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lungEva Szabo
Journal of the National Cancer Institute|November 1, 2007
Proliferative changes in chemoprevention trials: learning from secondary endpointsEva Szabo
Methods in Molecular Medicine|November 6, 2002
MUC1 expression in lung cancerEva Szabo
Ecancermedicalscience|December 5, 2015
Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experienceEva Szabo
Seminars in Oncology|September 7, 2010
Phase II cancer prevention clinical trialsEva Szabo
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancyEva Szabo
Nature Clinical Practice. Oncology|May 1, 2008
Primer: first do no harm--when is it appropriate to plan a cancer prevention clinical trial?Eva Szabo
Nature Reviews. Cancer|October 13, 2006
Selecting targets for cancer prevention: where do we go from here?Eva Szabo
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Altered histology provides a positive clinical signal in the bronchial epitheliumEva Szabo
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 9, 2003
Chemoprevention of lung cancer: new directionsEva Szabo, Thea Kalebic
Pageof 22

Showing results (1-10 of 220) with videos related to

Sort By:
Pageof 22
Cancer Prevention Research (Philadelphia, Pa.)|January 28, 2010
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lungEva Szabo
Journal of the National Cancer Institute|November 1, 2007
Proliferative changes in chemoprevention trials: learning from secondary endpointsEva Szabo
Methods in Molecular Medicine|November 6, 2002
MUC1 expression in lung cancerEva Szabo
Ecancermedicalscience|December 5, 2015
Biomarkers in phase I-II chemoprevention trials: lessons from the NCI experienceEva Szabo
Seminars in Oncology|September 7, 2010
Phase II cancer prevention clinical trialsEva Szabo
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancyEva Szabo
Nature Clinical Practice. Oncology|May 1, 2008
Primer: first do no harm--when is it appropriate to plan a cancer prevention clinical trial?Eva Szabo
Nature Reviews. Cancer|October 13, 2006
Selecting targets for cancer prevention: where do we go from here?Eva Szabo
Cancer Prevention Research (Philadelphia, Pa.)|June 4, 2011
Altered histology provides a positive clinical signal in the bronchial epitheliumEva Szabo
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 9, 2003
Chemoprevention of lung cancer: new directionsEva Szabo, Thea Kalebic
Pageof 22